Patrick M Forde (Patrick Forde, P M Forde)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 40

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Liver Metastases

Top Venues

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research communications

Nature reviews. Clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer research communications 4 (3) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer research communications 4 (3) (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC. Cancer research communications (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC. Cancer research communications (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC. Cancer research communications (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa Lynne Johnson, Sophie Cousin, Dong Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John Victor Heymach
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature medicine 30 (3) (2024)
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J Falcon, Patrick Evans, Josephine Feliciano, Christine L Hann, David S Ettinger, Kellie N Smit, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin Levy, Alexander E Drilon, Vincent K Lam
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer research communications 4 (3) (2024)
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James Robert White, Noushin Niknafs, Lamia Rhymee, Gavin Pereira, Nisha Rao, Benny Weksler, Nathan Bahary, Jillian A Phallen, Alessandro Leal, David L Bartlett, Kristen A Marrone, Jarushka Naidoo, Akul Goel, Benjamin Levy, Samuel Rosner, Christine L Hann, Susan C Scott, Josephine Feliciano, Vincent K Lam, David S Ettinger, Qing Kay Li, Peter B Illei, Kim Monkhorst, Robert B Scharpf, Julie R Brahmer, Victor E Velculescu, Blair A Jobe, Patrick M Forde, Valsamo Anagnostou
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine 29 (2) (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (4) (2023)
Michael R Conroy, Patrick M Forde
Advancing neoadjuvant immunotherapy for lung cancer. Nature medicine (2023)
Michael R Conroy, Patrick M Forde
Advancing neoadjuvant immunotherapy for lung cancer. Nature medicine 29 (3) (2023)
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M Forde, Jonathan D Spicer, Nicolas Girard, Daphne Wang, Robert A Anders, Edward Gabrielson, Peter Illei, Jaroslaw Jedrych, Ludmila V Danilova, Joel C Sunshine, Keith M Kerr, Mia Tran, Judy Bushong, Junliang Cai, Vipul Devas, Jaclyn Neely, David Balli, Tricia R Cottrell, Alexander S Baras, Janis M Taube
Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nature medicine (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (4) (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (4) (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Griffin, Natalie I Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M Forde, Valsamo Anagnostou, Jonathan W Riess, Don L Gibbons, Nathan A Pennell, Vamsidhar Velcheti, Subba R Digumarthy, Mari A Mino-Kenudson, Andrea Califano, John Victor Heymach, Roy S Herbst, Julie R Brahmer, Kurt A Schalper, Victor E Velculescu, Brian S Henick, Naiyer Rizvi, Pasi A Janne, Mark M Awad, Andrew Chow, Benjamin D Greenbaum, Marta Luksza, Alice T Shaw, Jedd D Wolchok, Nir Hacohen, Gad A Getz, Justin F Gainor
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature genetics (2023)
Cascone Tina, Gozde Kar, Jonathan D Spicer, María Del Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Júlio Oliveira, Edwin H Yau, Alexander I Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge M Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M Forde
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial. Cancer discovery (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine 29 (2) (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine 29 (2) (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (4) (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine 29 (2) (2023)
Samuel Rosner, Joshua E Reuss, Marianna L Zahurak, Jiajia Zhang, Zhen Zeng, Janis M Taube, Valsamo Anagnostou, Kellie N Smit, Joanne Riemer, Peter B Illei, Stephen R Broderick, David R Jones, Suzanne L Topalian, Drew M Pardoll, Julie R Brahmer, Jamie E Chaft, Patrick M Forde
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (4) (2023)
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph C Murray, Kellie N Smit, Benjamin Levy, Josephine Feliciano, Christine L Hann, Vincent Lam, Drew M Pardoll, Rachel Karchin, Tanguy Y Seiwert, Julie R Brahmer, Patrick M Forde, Victor E Velculescu, Valsamo Anagnostou
Persistent mutation burden drives sustained anti-tumor immune responses. Nature medicine 29 (2) (2023)
Arbor G Dykema, Jiajia Zhang, Laurene S Cheung, Sydney Connor, Boyang Zhang, Zhen Zeng, Christopher M Cherry, Taibo Li, Justina X Caushi, Marni Nishimoto, Andrew J Munoz, Zhicheng Ji, Wenpin Hou, Wentao Zhan, Dipika Singh, Tianbei Zhang, Rufiaat Rashid, Marisa Mitchell-Flack, Sadhana Bom, Ada Tam, Nick Ionta, Thet H K Aye, Yi Wang, Camille A Sawosik, Lauren E Tirado, Luke M Tomasovic, Derek VanDyke, Jamie B Spangler, Valsamo Anagnostou, Stephen Yang, Jonathan D Spicer, Roni Rayes, Janis M Taube, Julie R Brahmer, Patrick M Forde, Srinivasan Yegnasubramanian, Hongkai Ji, Drew M Pardoll, Kellie N Smit
Lung tumor-infiltrating T reg have divergent transcriptional profiles and function linked to checkpoint blockade response. Science immunology 8 (87) (2023)
Giannis S Mountzios, Jordi Remon, Lizza E L Hendriks, Rosario García-Campelo, Christian C Rolfo, Paul Van Schil, Patrick M Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nature reviews. Clinical oncology (2023)
Aaron S Mansfield, Zihan Wei, R Mehra, A T Shaw, Christopher H Lieu, Patrick M Forde, Alexander E Drilon, E P Mitchell, J J Wright, N Takebe, E Sharon, Daniel H Hovelson, S Tomlins, J Zeng, K Poorman, N Malik, Robert C Gray, S Li, L M McShane, Lawrence V Rubinstein, David R Patton, P Mickey Williams, S R Hamilton, B A Conley, C L Arteaga, L N Harris, P J O'Dwyer, A P Chen, K T Flaherty
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ precision oncology 6 (1) (2022)
Sara E Schad, Andrew Chow, Levi Mark Mangarin, Heng Pan, Jiajia Zhang, Nicholas Ceglia, Justina X Caushi, Nicole Malandro, Roberta Zappasodi, Mathieu Gigoux, Daniel Hirschhorn, Sadna Budhu, Masataka Amisaki, Monica B Arniella, David Redmond, Jamie E Chaft, Patrick M Forde, Justin F Gainor, Matthew D Hellmann, Vinod P Balachandran, Sohrab P Shah, Kellie N Smit, Drew M Pardoll, Olivier Elemento, Jedd D Wolchok, Taha Merghoub
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. The Journal of experimental medicine 219 (6) (2022)
Valsamo Anagnostou, Blair V Landon, Jamie E Medina, Patrick M Forde, Victor E Velculescu
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Science translational medicine 14 (670) (2022)
Patrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E Dahlberg, Hedy L Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N Smith, Archana Balan, James R White, Christopher Cherry, I K Ashok Sivakumar, Xiaoshan M Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B Illei, Drew M Pardoll, Rachel Karchin, Victor E Velculescu, Julie R Brahmer, Suresh R Ramalingam
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine 27 (11) (2021)